These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 18729019)

  • 21. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimization of Fc-mediated effector functions of monoclonal antibodies.
    Strohl WR
    Curr Opin Biotechnol; 2009 Dec; 20(6):685-91. PubMed ID: 19896358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies and genetically engineered related molecules: production and purification.
    Roque AC; Lowe CR; Taipa MA
    Biotechnol Prog; 2004; 20(3):639-54. PubMed ID: 15176864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody modeling: implications for engineering and design.
    Morea V; Lesk AM; Tramontano A
    Methods; 2000 Mar; 20(3):267-79. PubMed ID: 10694450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two.
    Parker MH; Chen Y; Danehy F; Dufu K; Ekstrom J; Getmanova E; Gokemeijer J; Xu L; Lipovsek D
    Protein Eng Des Sel; 2005 Sep; 18(9):435-44. PubMed ID: 16087651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycosylation of recombinant antibody therapeutics.
    Jefferis R
    Biotechnol Prog; 2005; 21(1):11-6. PubMed ID: 15903235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Domain antibodies: proteins for therapy.
    Holt LJ; Herring C; Jespers LS; Woolven BP; Tomlinson IM
    Trends Biotechnol; 2003 Nov; 21(11):484-90. PubMed ID: 14573361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characterization and analysis of the aggregation of a single-chain chimeric anti-ErbB2 antibody].
    Zhu J; Rong Z; Jiang B; Liu J
    Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1918-23. PubMed ID: 19256339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction to current and future protein therapeutics: a protein engineering perspective.
    Carter PJ
    Exp Cell Res; 2011 May; 317(9):1261-9. PubMed ID: 21371474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
    Deyev SM; Lebedenko EN
    Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant approaches to IgG-like bispecific antibodies.
    Marvin JS; Zhu Z
    Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability.
    Röthlisberger D; Honegger A; Plückthun A
    J Mol Biol; 2005 Apr; 347(4):773-89. PubMed ID: 15769469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering aggregation-resistant antibodies.
    Perchiacca JM; Tessier PM
    Annu Rev Chem Biomol Eng; 2012; 3():263-86. PubMed ID: 22468604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.
    Stork R; Müller D; Kontermann RE
    Protein Eng Des Sel; 2007 Nov; 20(11):569-76. PubMed ID: 17982179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms.
    Monsellier E; Bedouelle H
    J Mol Biol; 2006 Sep; 362(3):580-93. PubMed ID: 16926023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct selection of antibodies from complex libraries with the protein fragment complementation assay.
    Koch H; Gräfe N; Schiess R; Plückthun A
    J Mol Biol; 2006 Mar; 357(2):427-41. PubMed ID: 16442560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and application of antibody cysteine variants.
    Voynov V; Chennamsetty N; Kayser V; Wallny HJ; Helk B; Trout BL
    Bioconjug Chem; 2010 Feb; 21(2):385-92. PubMed ID: 20092294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.